KYPROLIS Trademark

Trademark Overview

On Thursday, July 8, 2010, a trademark application was filed for KYPROLIS with the United States Patent and Trademark Office. The USPTO has given the KYPROLIS trademark a serial number of 85080817. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 21, 2014. This trademark is owned by Onyx Pharmaceuticals, Inc.. The KYPROLIS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Human pharmaceuticals for use in the prevention of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders; human pharmaceuticals for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amylodiosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders

Pharmaceutical research and development; medical and scientific research, namely, conducting clinical trials; medical and scientific research in the fields of treatment for cancer and oncology, and in the fields of treatment of inflammation and autoimmune diseases
kyprolis

General Information

Serial Number85080817
Word MarkKYPROLIS
Filing DateThursday, July 8, 2010
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 21, 2014
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 19, 2011

Trademark Statements

Goods and ServicesHuman pharmaceuticals for use in the prevention of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders; human pharmaceuticals for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amylodiosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders
Goods and ServicesPharmaceutical research and development; medical and scientific research, namely, conducting clinical trials; medical and scientific research in the fields of treatment for cancer and oncology, and in the fields of treatment of inflammation and autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 13, 2010
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, July 13, 2010
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameOnyx Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameOnyx Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressEmeryville, CA 94608

Trademark Events

Event DateEvent Description
Monday, July 21, 2014ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, July 21, 2014ABANDONMENT - NO USE STATEMENT FILED
Thursday, February 20, 2014ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 20, 2014TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 20, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 19, 2013EXTENSION 5 GRANTED
Thursday, November 14, 2013EXTENSION 5 FILED
Thursday, November 14, 2013TEAS EXTENSION RECEIVED
Friday, June 7, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 6, 2013EXTENSION 4 GRANTED
Tuesday, June 4, 2013EXTENSION 4 FILED
Tuesday, June 4, 2013TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 4, 2013TEAS EXTENSION RECEIVED
Thursday, November 8, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 8, 2012CORRECTED NOA E-MAILED
Wednesday, November 7, 2012EXTENSION 3 GRANTED
Monday, October 22, 2012EXTENSION 3 FILED
Wednesday, November 7, 2012DIVISIONAL PROCESSING COMPLETE
Monday, October 22, 2012DIVISIONAL REQUEST RECEIVED
Monday, October 22, 2012TEAS REQUEST TO DIVIDE RECEIVED
Monday, October 22, 2012TEAS EXTENSION RECEIVED
Friday, May 25, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 24, 2012EXTENSION 2 GRANTED
Monday, May 21, 2012EXTENSION 2 FILED
Monday, May 21, 2012TEAS EXTENSION RECEIVED
Friday, December 9, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 8, 2011EXTENSION 1 GRANTED
Tuesday, November 29, 2011EXTENSION 1 FILED
Thursday, December 8, 2011CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, November 29, 2011TEAS EXTENSION RECEIVED
Tuesday, June 14, 2011NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, May 19, 2011APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, May 19, 2011TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, April 19, 2011OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 19, 2011PUBLISHED FOR OPPOSITION
Thursday, March 17, 2011LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, March 17, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, March 17, 2011TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 17, 2011CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 15, 2011ASSIGNED TO LIE
Thursday, March 3, 2011TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, September 5, 2010NOTIFICATION OF PRIORITY ACTION E-MAILED
Sunday, September 5, 2010PRIORITY ACTION E-MAILED
Sunday, September 5, 2010PRIORITY ACTION WRITTEN
Sunday, August 29, 2010ASSIGNED TO EXAMINER
Tuesday, July 13, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, July 12, 2010NEW APPLICATION ENTERED IN TRAM

Related Keywords

kyprolis diseases disorders autoimmune treatment inflammation tumors research fields scientific medical